EA201891261A1 - Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний - Google Patents

Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний

Info

Publication number
EA201891261A1
EA201891261A1 EA201891261A EA201891261A EA201891261A1 EA 201891261 A1 EA201891261 A1 EA 201891261A1 EA 201891261 A EA201891261 A EA 201891261A EA 201891261 A EA201891261 A EA 201891261A EA 201891261 A1 EA201891261 A1 EA 201891261A1
Authority
EA
Eurasian Patent Office
Prior art keywords
eosinophilic
derivatives
treatment
glutarimid
application
Prior art date
Application number
EA201891261A
Other languages
English (en)
Other versions
EA032940B1 (ru
Inventor
Владимир Евгеньевич НЕБОЛЬСИН
Татьяна Александровна КРОМОВА
Анастасия Владимировна РЫДЛОВСКАЯ
Александр Григорьевич ЧУЧАЛИН
Original Assignee
Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Фарминтерпрайсез" filed Critical Общество С Ограниченной Ответственностью "Фарминтерпрайсез"
Publication of EA201891261A1 publication Critical patent/EA201891261A1/ru
Publication of EA032940B1 publication Critical patent/EA032940B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к новым биологически активным производным глутаримидов общей формулы (I) или их фармацевтически приемлемым солям, их применению в качестве средств для лечения эозинофильных заболеваний, преимущественно аллергической природы, в частности бронхиальной астмы, аллергического ринита, полипозной ринусиносопатии, эозинофильного колита, эозинофильного синдрома, аллергического конъюктивита, атопического дерматита, синдрома Черджа-Стросса, анафилактического шока, отека Квинке, эозинофильного васкулита, эозинофильного эзофагита, эозинофильного гастроэнтерита, фиброзов, фармацевтическим композициям, содержащим производные глутаримидов общей формулы (I).
EA201891261A 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов EA032940B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2013150861/15A RU2552929C1 (ru) 2013-11-14 2013-11-14 Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Publications (2)

Publication Number Publication Date
EA201891261A1 true EA201891261A1 (ru) 2018-10-31
EA032940B1 EA032940B1 (ru) 2019-08-30

Family

ID=53057723

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний
EA201891261A EA032940B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний с помощью соединения производного глутаримидов
EA201690798A EA030961B1 (ru) 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний
EA201891262A EA032955B3 (ru) 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201990529A EA037447B1 (ru) 2013-11-14 2014-11-12 Способ лечения эозинофильных заболеваний

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201690798A EA030961B1 (ru) 2013-11-14 2014-11-12 Применение производных глутаримидов для лечения эозинофильных заболеваний
EA201891262A EA032955B3 (ru) 2013-11-14 2014-11-12 Применение производного глутаримида для лечения эозинофильных заболеваний

Country Status (23)

Country Link
US (2) US9949962B2 (ru)
EP (2) EP3069720B1 (ru)
JP (4) JP2016540749A (ru)
KR (2) KR102312294B1 (ru)
CN (2) CN110200968A (ru)
AU (2) AU2014349246C1 (ru)
BR (1) BR112016010515B1 (ru)
CA (1) CA2930231C (ru)
CY (1) CY1122500T1 (ru)
DK (1) DK3069720T3 (ru)
EA (4) EA037447B1 (ru)
ES (2) ES2836887T3 (ru)
HU (1) HUE046671T2 (ru)
IL (2) IL245429B (ru)
LT (1) LT3069720T (ru)
MX (2) MX365781B (ru)
PL (2) PL3069720T3 (ru)
PT (1) PT3069720T (ru)
RU (1) RU2552929C1 (ru)
SG (1) SG10201900504XA (ru)
SI (1) SI3069720T1 (ru)
UA (1) UA118687C2 (ru)
WO (1) WO2015072893A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015025804B1 (pt) * 2013-04-12 2022-01-04 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR20160120735A (ko) 2014-02-28 2016-10-18 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
WO2018045130A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
CN106539792B (zh) * 2016-11-07 2017-08-25 王晓旭 一种治疗高血脂症的药物
EA201992341A8 (ru) 2017-09-07 2020-08-11 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов
RU2712281C1 (ru) 2018-11-23 2020-01-28 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CA3147068A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
MA58653B1 (fr) * 2020-06-26 2024-02-29 Valenta Intellekt Ltd Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6
WO2023113650A1 (ru) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02196767A (ja) * 1988-10-11 1990-08-03 Kyowa Hakko Kogyo Co Ltd ヒドロキサム酸誘導体
WO1992011011A1 (en) * 1990-12-24 1992-07-09 Merrell Dow Pharmaceuticals Inc. Use of certain glutarimide derivatives in the treatment of depression and mania
AU6702894A (en) * 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
RU2141483C1 (ru) 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
DK1443960T3 (da) 2001-11-07 2009-03-23 Cytos Biotechnology Ag Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme
EP1741709A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals
WO2007007054A1 (en) 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
MX2009012341A (es) 2007-05-14 2010-02-17 Medimmune Llc Metodos para reducir niveles de eosinofilos.
RU2406727C2 (ru) * 2008-02-13 2010-12-20 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств
RU2378284C2 (ru) * 2008-02-13 2010-01-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способы получения n-ацильных производных аминокислот (варианты)
BR112015025804B1 (pt) 2013-04-12 2022-01-04 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" Derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida

Also Published As

Publication number Publication date
EP3069720B1 (en) 2019-10-30
CY1122500T1 (el) 2021-01-27
CN105722511B (zh) 2019-09-17
CN105722511A (zh) 2016-06-29
ES2759530T3 (es) 2020-05-11
SI3069720T1 (sl) 2020-02-28
EP3466425B1 (en) 2020-10-07
CA2930231A1 (en) 2015-05-21
IL271352A (en) 2020-01-30
EA201690798A1 (ru) 2016-08-31
EA032955B1 (ru) 2019-08-30
EA032940B1 (ru) 2019-08-30
EP3069720A1 (en) 2016-09-21
PT3069720T (pt) 2019-12-02
MX365781B (es) 2019-06-13
US9949962B2 (en) 2018-04-24
PL3466425T3 (pl) 2021-04-06
IL245429B (en) 2020-02-27
EP3069720A4 (en) 2017-06-21
KR102312013B1 (ko) 2021-10-15
UA118687C2 (ru) 2019-02-25
DK3069720T3 (da) 2019-11-25
AU2018264084B2 (en) 2020-05-14
EA032955B3 (ru) 2020-02-27
KR20200053639A (ko) 2020-05-18
MX2019006881A (es) 2019-08-01
BR112016010515A2 (ru) 2017-08-08
ES2836887T3 (es) 2021-06-28
KR20160078400A (ko) 2016-07-04
PL3069720T3 (pl) 2020-05-18
US20160279114A1 (en) 2016-09-29
JP6589251B2 (ja) 2019-10-16
WO2015072893A1 (ru) 2015-05-21
CN110200968A (zh) 2019-09-06
AU2014349246B2 (en) 2018-10-18
AU2018264084C1 (en) 2020-08-27
US10220029B2 (en) 2019-03-05
EA037447B1 (ru) 2021-03-30
HUE046671T2 (hu) 2020-03-30
US20180104230A1 (en) 2018-04-19
AU2014349246A1 (en) 2016-05-19
CA2930231C (en) 2022-06-14
RU2552929C1 (ru) 2015-06-10
MX2016006330A (es) 2016-09-06
EA201891262A1 (ru) 2018-10-31
AU2014349246A9 (en) 2018-09-20
IL245429A0 (en) 2016-06-30
AU2018264084A1 (en) 2018-12-06
JP2016540749A (ja) 2016-12-28
LT3069720T (lt) 2020-01-10
EA030961B1 (ru) 2018-10-31
JP2019214606A (ja) 2019-12-19
JP2019055953A (ja) 2019-04-11
EP3466425A1 (en) 2019-04-10
SG10201900504XA (en) 2019-02-27
EA201990529A1 (ru) 2019-07-31
KR102312294B1 (ko) 2021-10-15
JP2020002152A (ja) 2020-01-09
AU2014349246C1 (en) 2019-02-21
BR112016010515B1 (pt) 2022-09-27
RU2013150861A (ru) 2015-05-20
EP3069720A8 (en) 2017-10-04
IL271352B (en) 2021-04-29
JP6758677B2 (ja) 2020-09-23

Similar Documents

Publication Publication Date Title
EA201891262A1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний
PH12017501478A1 (en) 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
TR201901886T4 (tr) DNA-PK inhibitörleri.
MD4800B1 (ru) Соединения аминопиримидинила в качестве ингибиторов JAK
NZ714710A (en) Phosphatidylinositol 3-kinase inhibitors
TN2016000017A1 (en) Piperidinyl indole derivatives and their use as complement factor b inhibitors
MD4666C1 (ru) Ингибиторы Syk
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201391615A1 (ru) Дейтерированные потенциаторы cftr
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
MD4820C1 (ru) Замещенные дигидроизохинолиноновые соединения
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
NZ719185A (en) Crystalline forms of therapeutic compounds and uses thereof
UA115357C2 (uk) Похідні піридин-4-ілу
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
CO2017011020A2 (es) Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k)
ECSP13013075A (es) Método de tratamiento de la fiebre dengue
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
MX2014001862A (es) 5-cicloalquil-o 5-heterociclil-nicotinamidas.
CA2920315C (en) Diphenyloxyalkylamine derivatives and aryloxyalkylamine derivatives, pharmaceutical composition, use of said pharmaceutical composition for treating, preventing or inhibiting chronic pulmonary inflammatory diseases and method for treating or preventing such diseases

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM

PC4A Registration of transfer of a eurasian patent by assignment